NASDAQ NMS - GLOBAL MARKET · DYN
+0.34% · +$0.0897 · Vol Not reported
Pre-market · updated 08:40:56 ET
Dyne Therapeutics, Inc

Dyne Therapeutics, Inc

Biotechnology
$26.34
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
DYN
Dyne Therapeutics, Inc
Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

70/ 100
Veridion Score
BUY BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is DYN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading DYN catalysts
About Dyne Therapeutics, Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
258
Country
US

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$26.25
Last session
Day high
$26.25
Last session
Day low
$26.25
Last session
Previous close
$26.25
52W high
$26.34
0.00% from high
52W low
$11.24
100% of range
Market cap
$4.9B
EPS
$-3.5400
Beta
1.35
Shares out
186.7M
Avg volume
2.6M
VWAP
$26.25
Last session
Price history computed in-house
1W
+4.36%
1M
+12.47%
3M
+43.38%
1Y
+136.02%
YTD
+34.66%
SMA 50 $21.90 · above
SMA 200 $19.35 · above
52W position 100%

DYN overview

Veridion Score
70
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around DYN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading DYN Form 4 filings
Public disclosures

Congress activity in DYN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for DYN in the cached public ledger.

Federal contracts

DYN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DYN in this window.
Lobbying spend

DYN lobbying filings, year to date.

Registered lobbying filings matched to Dyne Therapeutics, Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DYN in this window.
Loading news for DYN
Analyst ratings
Sovereign unlock shows live analyst consensus for DYN.
Options
Sovereign unlock shows live options positioning for DYN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.